Denosumab: a review in postmenopausal osteoporosis
ED Deeks - Drugs & aging, 2018 - Springer
Abstract Denosumab (Prolia®; Pralia®) is a human monoclonal antibody targeting the key
bone resorption mediator RANKL. The drug is administered via subcutaneous injection once …
bone resorption mediator RANKL. The drug is administered via subcutaneous injection once …
A systematic review of factors affecting medication adherence among patients with osteoporosis
The aim of this review was to identify factors that influence patients' adherence to anti-
osteoporotic therapy. Factors identified that were associated with poorer medication …
osteoporotic therapy. Factors identified that were associated with poorer medication …
Cancel the denosumab holiday
MR McClung - Osteoporosis International, 2016 - Springer
Denosumab, a fully human IgG2 anti-RANK ligand antibody, quickly and substantially
inhibits bone remodeling [1]. As expected by the pharmacology of denosumab, this inhibition …
inhibits bone remodeling [1]. As expected by the pharmacology of denosumab, this inhibition …
Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink
J Morley, A Moayyeri, L Ali, A Taylor… - Osteoporosis …, 2020 - Springer
Gaining full benefits from osteoporosis medications requires long-term treatment.
Investigating the real-world persistence of women receiving osteoporosis medications in the …
Investigating the real-world persistence of women receiving osteoporosis medications in the …
Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss
Introduction: Pharmacological options to address the imbalance between bone resorption
and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique …
and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique …
Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years
A Modi, S Sajjan, R Insinga, J Weaver… - Osteoporosis …, 2017 - Springer
Little is known about treatment patterns with injectable osteoporosis therapies. At 12 months,
the probability of discontinuation was 69.1% among patients using ibandronate, followed by …
the probability of discontinuation was 69.1% among patients using ibandronate, followed by …
Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study …
COVID-19 lockdowns have impacted management of chronic diseases such as
osteoporosis. Adherence to the 6-monthly dosing schedule of denosumab, the parenteral …
osteoporosis. Adherence to the 6-monthly dosing schedule of denosumab, the parenteral …
Patient-related factors associated with adherence to recommendations made by a fracture liaison service: a mixed-method prospective study
A Fracture Liaison Service (FLS) has been calculated to be a cost-effective model of care for
patients with fragility fracture (FF). Cost-effectiveness can be achieved when adherence to …
patients with fragility fracture (FF). Cost-effectiveness can be achieved when adherence to …
Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study
DM Borek, RC Smith, CN Gruber, BL Gruber - Osteoporosis International, 2019 - Springer
Persistence rates over 36 months with denosumab in patients diagnosed with osteoporosis
in a real-world setting were examined, along with baseline patient characteristics predictive …
in a real-world setting were examined, along with baseline patient characteristics predictive …
Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap
JK Ban, BB Hao, L McCarthy, SJT Guilcher… - Osteoporosis …, 2019 - Springer
We studied 46,797 older adults who initiated denosumab in Ontario, Canada. Patient
characteristics remained relatively stable over time and aligned with public reimbursement …
characteristics remained relatively stable over time and aligned with public reimbursement …